Company intelligence / Profile preview

Tome Biosciences

Watertown, Massachusetts, United Statestlo.mit.edu ↗

Ownership: Private
Employees: ~150
Development stage: Preclinical

Overview

Tome Biosciences launched in December 2023 with $213 million in funding to develop its Programmable Genomic Integration technology. Despite promising technology, the company struggled financially and by August 2024 had pared down operations to explore "strategic options." By November 2024, the company had laid off all employees. The company had achieved 8% PGI in bulk liver alleles in non-human primates for the PAH locus, which is mutated in phenylketonuria (PKU)[3].

Therapeutic areas: Rare DiseasesMetabolic DisordersCardiovascularImmunology
Modalities: Gene editingCRISPR/Cas9CAR-NK
Industry: Biotech

Partnerships

Genevant Sciences

Beyond the preview

Go deeper on Tome Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tome Biosciences.

Explore the full profile